Meeting News

Armored CAR T cells safe, clinically active in advanced pediatric liver cancer

May 21, 2020
A novel armored chimeric antigen receptor T-cell therapy targeting the glypican-3 protein showed antitumor activity among children with advanced…
FDA News

FDA clears IND application for CAR T-cell therapy targeting gastric, pancreatic cancers

May 20, 2020
The FDA cleared an investigational new drug application for CT041, a chimeric antigen receptor T-cell therapy for the treatment of adenocarcinoma of…

Regimen extends PFS in relapsed multiple myeloma

May 19, 2020
The addition of isatuximab-irfc to carfilzomib and dexamethasone significantly prolonged PFS among patients with relapsed multiple myeloma, according…
Meeting News

CAR-natural killer T-cell therapy feasible, safe for advanced neuroblastoma

May 19, 2020
A modified natural killer T-cell therapy expressing a chimeric antigen receptor and interleukin-15 appeared feasible and safe for children with…
FDA News

FDA expands Tecentriq approval for metastatic lung cancer

May 18, 2020
The FDA expanded the approval of atezolizumab to include first-line monotherapy of patients with metastatic non-small cell lung cancer whose tumors…
In the JournalsPerspective

Higher dose of CAR T cells may be more effective in advanced chronic lymphocytic leukemia

May 18, 2020
A higher dose of anti-CD19 chimeric antigen receptor T cells may lead to more complete responses among patients with relapsed or refractory chronic…
FDA News

FDA approves immunotherapy combination for first-line treatment of metastatic NSCLC

May 15, 2020
The FDA approved nivolumab plus ipilimumab for first-line treatment of patients with metastatic non-small cell lung cancer whose tumors express…
In the Journals

Atezolizumab plus bevacizumab improves survival outcomes vs. sorafenib in unresectable HCC

May 13, 2020
Atezolizumab in combination with bevacizumab improved OS and PFS compared with sorafenib among patients with unresectable hepatocellular carcinoma…
FDA News

FDA delays application for investigational CAR-T for advanced multiple myeloma

May 13, 2020
The FDA has issued a refusal to file letter regarding the biologics license application of the investigational chimeric antigen receptor T-cell…

Cleveland Clinic appoints immunotherapy center director

May 13, 2020
Timothy Chan, MD, PhD, has been appointed director of Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic. The center brings…
Healio Jobs